Arcus Biosciences, Inc. (RCUS) Stock Analysis

Q: What is the RCUS stock price target?

Take-profit $30.29 (+32.2% upside). Prior stop was $21.93.

Q: What are the risks of investing in RCUS?

Concentration risk — Counterparty: Gilead; Concentration risk — Supplier: WuXi Biologics; Quality below floor (2.7 < 4.0); Quality below floor (2.7 < 4.0); Momentum score 2.1/10 — below 4.5 minimum.

Q: Is RCUS overvalued or undervalued?

Arcus Biosciences, Inc. trades at a P/E of N/A (forward -7.4). TrendMatrix value score: 6.1/10. Overall verdict: Sell.

Q: What do analysts say about RCUS?

18 analysts cover RCUS with a consensus score of 4.1/5. Average price target: $35.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 1 days ago (May 19, 2026, 2:56 PM ET)

Healthcare · Biotechnology

$22.86+32.2% A.UpsideScore 4.0/10#148 of 157 Biotechnology

QualityF-score3 / 9FCF yield-5.30%

Stop $21.93Target $30.29(analyst − 13%)A.R:R 3.0:1

Analyst target$34.82+52.3%11 analysts

$30.29our TP

$22.86price

$34.82mean

$47

Sell if holding. Engine safety override at $22.86: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.0/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Arcus Biosciences, Inc.

Latest news

Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35 — benzinga May 18, 2026 positive
Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22 — benzinga May 11, 2026 neutral
Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34 — benzinga May 7, 2026 positive
Arcus Biosciences Q1 EPS $(1.02) Misses $(0.93) Estimate, Sales $17.000M Miss $29.484M Estimate — benzinga May 5, 2026 negative
Earnings Scheduled For May 5, 2026 — benzinga May 5, 2026 neutral

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

Recent Analyst detected in news

Risks

Concentration risk — Counterparty: Gilead

Concentration risk — Supplier: WuXi Biologics

Quality below floor (2.7 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-7.4

Mkt Cap$2.9B

EV/EBITDA-5.7

Profit Mgn-156.4%

ROE-70.0%

Rev Growth-39.3%

Beta0.87

DividendNone

Rating analysts18

Quality Signals

Piotroski F3/9

Options Flow

P/C0.12bullish

IV78%elevated

Max Pain$15-34.4% vs spot

Concentration Risks(10-K Item 1A)

HIGHcounterpartyGilead
10-K Item 1A: 'We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of certain of our investigational products. If this collaboration is not successful, our business could be adversely affected.'
HIGHSupplierWuXi Biologics
10-K Item 1: 'we agreed, as part of the WuXi PD-1 Agreement, that WuXi Biologics would be our exclusive manufacturer of zimberelimab drug substance with respect to clinical and commercial supplies until a certain number of years after marketing approval'

Material Events(8-K, last 90d)

2026-03-23Item 5.02MEDIUM
On March 17, 2026, Jennifer Jarrett (Chief Operating Officer) resigned effective March 30, 2026, to pursue other opportunities. She will provide advisory services through June 30, 2026. No successor named. No disagreement cited.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value6.115%0.91

Quality2.715%0.41

Growth0.015%0.00

Momentum2.110%0.21

Sentiment8.710%0.87

Insider Activity5.010%0.50

Peer Rank1.610%0.16

Technical Setup8.55%0.43

Risk Profile4.55%0.23

Catalyst6.15%0.30

Overall (Σ contributions)4.02

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Revenue shrinking — -39.3% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth

0.0

Declining revenue: -39%

Low model confidence on this dimension (33%).

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.4

Growth Rank

2.0

Value Rank

4.0

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Ma Position

4.0

Rsi

5.5

Volume distribution (falling OBV)Above 200-day MA

Unprofitable operations — net margin -156.4%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Fcf Quality

0.0

Piotroski F

3.3

Moat

4.0

Current Ratio

9.0

Cash-burning: FCF -66% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

GatesMomentum 2.1<4.5A.R:R 3.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70EARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

41 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $22.61Resistance $28.72

Price Targets

$22

$30

A.Upside+32.5%

A.R:R3.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (2.7 < 4.0)

! Momentum score 2.1/10 — below 4.5 minimum

Earnings

2/4 beats

Next Earnings2026-08-05 (78d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is RCUS stock a buy right now?

Sell if holding. Engine safety override at $22.86: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $21.93. Score 4.0/10, moderate confidence.

What is the RCUS stock price target?

Take-profit target: $30.29 (+32.2% upside). Prior stop was $21.93. Stop-loss: $21.93.

What are the risks of investing in RCUS?

Concentration risk — Counterparty: Gilead; Concentration risk — Supplier: WuXi Biologics; Quality below floor (2.7 < 4.0).

Is RCUS overvalued or undervalued?

Arcus Biosciences, Inc. trades at a P/E of N/A (forward -7.4). TrendMatrix value score: 6.1/10. Verdict: Sell.

What do analysts say about RCUS?

18 analysts cover RCUS with a consensus score of 4.1/5. Average price target: $35.

What does Arcus Biosciences, Inc. do?Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated oncology and...

Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated oncology and inflammation molecules, with lead programs casdatifan (HIF-2α, two Phase 3 trials in ccRCC), quemliclustat (CD73, Phase 3 in pancreatic cancer), and domvanalimab/zimberelimab (anti-TIGIT/PD-1, Phase 3 in NSCLC). The Gilead collaboration funds a significant portion of development costs and controls ex-U.S. commercialization rights for quemliclustat, domvanalimab, and zimberelimab. The company has no approved products and generates revenue primarily from collaboration payments.